about
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceUtilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myelomaPhase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursingDexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesisScreening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin.Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice.Thalidomide and its derivatives: emerging from the wilderness.Proteasome inhibition in hematologic malignancies.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study.A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody.Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells.Myeloma cells with asurophilic granules--an unusual morphological variant--case presentationDetection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.Thalidomide as initial therapy for early-stage myeloma.Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot study.
P2860
Q24669898-8FBD7DDD-5442-4915-8089-114D76684835Q28544663-AD21B0A0-42BF-4B12-AB11-05CB3C930E90Q33404348-5D048382-6A34-486A-BFBF-CE4AFA6F46F4Q34361282-1702506E-13A2-4D95-B919-976FBBE16A8BQ34411693-65AC8A46-4187-4260-8ACC-6FDE37C0F89DQ34656161-C17BCA34-A2DC-4F66-B0C4-6264467C5973Q34733945-0910D3AF-AC10-4E19-9811-576A53EED764Q35107977-EE201913-BE0F-4EED-8F5C-7605D551D26BQ35821602-520AF919-236E-4766-9F75-FBC76F76B468Q36171864-7A8D9B2E-5C03-4E53-9E9A-FDAC1771FB2FQ36628641-1B1591A9-4790-4627-8828-78A86C77FE53Q37009725-38E6CF2D-70DD-4F0D-9A93-6F5DD01422B2Q37509952-C14E68A7-E31F-4DEB-B17B-23629122051FQ37940343-0E9D68A8-F95E-4118-BAA4-125F59F84B61Q39002186-C3E9267B-CF00-4D36-9260-19E76432ACA7Q39842258-2698BA68-F470-44FE-ADB7-0A9A3A54301AQ40388164-49777649-5994-46BA-951F-AD8FEB6F9337Q41937781-A9E83B59-C93C-431D-96F7-CC09DB12A640Q43100815-B0E53CF6-AD68-4723-877E-566602D46EB4Q44394897-DCCAC5B2-83BA-40C3-8998-A6E6F593658FQ44915727-7F25D1FA-F6C3-421D-93B5-C75AC0AB61C3Q45138883-B73F4956-D68C-445A-9F2B-691BC41EA891Q47572205-A0FBFEC2-5430-44DD-B7C0-72FDFA2C5737
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current therapy for multiple myeloma.
@ast
Current therapy for multiple myeloma.
@en
Current therapy for multiple myeloma.
@nl
type
label
Current therapy for multiple myeloma.
@ast
Current therapy for multiple myeloma.
@en
Current therapy for multiple myeloma.
@nl
prefLabel
Current therapy for multiple myeloma.
@ast
Current therapy for multiple myeloma.
@en
Current therapy for multiple myeloma.
@nl
P50
P356
P1476
Current therapy for multiple myeloma.
@en
P2093
Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group
Philip R Greipp
P304
P356
10.4065/77.8.813
P407
P577
2002-08-01T00:00:00Z